BioBio schreef op 26 januari 2021 08:41:
Wat wil je nog meer horen van de CEO........
Slide 9
Investment to increase capacity due to strong demand Investment to increase capacity due to strong demand
Underlying demand for RUCONEST® increasing further in both US and RoW
• At the beginning of 2020, Pharming received both European Medicines Agency (EMA) and US Food and
Drug Administration (FDA) approval of its new production facility of starting material for RUCONEST®
• Work initiated on a third facility to safeguard future growth in HAE supplies
• Plans for a larger fourth facility to manufacture our other pipeline products
• Strategic investment supports capacity expansion that will help Pharming to meet growing demand for
RUCONEST® and long-term expansion of pipeline
Patient numbers in new indications in pre-eclampsia, acute kidney injury and severe pneumonia as a result of
COVID-19 infection are much larger than for HAE
Re-developing rhC1INH from cattle as a new variant to meet future demand for these such large indications
In addition, building our own downstream processing facility (to purify the drug from the milk) will enable us to
perfect in-house process before anticipated positive clinical data in new indications
Capacity will only be built on a conservative as-needed basis, bearing in mind lead times, cost and scale involved
Funding will come from current cash generation